NAD+: What the Research Shows About Cellular Energy and Longevity

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell of the human body. It sits at the centre of energy metabolism, DNA repair, and cellular stress response. And its levels decline measurably with age — a fact that has made it one of the most studied targets in longevity research.

What Is NAD+?

NAD+ is not a peptide in the traditional sense. It is a dinucleotide — two nucleotides joined by phosphate groups — that functions as an essential electron carrier in cellular metabolism. Every cell requires it to produce ATP, the body's primary energy currency.

Beyond energy production, NAD+ is a required substrate for two critical enzyme classes:

• Sirtuins (SIRT1–7): Often called "longevity proteins," sirtuins regulate DNA repair, gene expression, mitochondrial biogenesis, and inflammation. They require NAD+ to function.
• PARP enzymes: Central to DNA damage detection and repair. PARP activation consumes NAD+, which is why cellular stress and DNA damage accelerate NAD+ depletion.

The Age-Related Decline

Research consistently shows that NAD+ levels fall with age. Studies in human tissue have found NAD+ concentrations in skin and muscle that are 40–60% lower in older adults compared to younger cohorts.

The proposed consequences of this decline align with hallmarks of aging: reduced mitochondrial efficiency, impaired DNA repair, increased cellular senescence, and declining sirtuin activity. Whether restoring NAD+ levels reverses these effects is the central question driving clinical research.

Administration Routes: Why IV and Subcutaneous?

Oral NAD+ precursors — primarily NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — are widely available. The rationale for IV or subcutaneous administration is bioavailability: these routes bypass first-pass metabolism and gastrointestinal absorption variability, delivering NAD+ or its precursors directly into systemic circulation.

IV NAD+ infusions have been used in clinical settings since the 1960s, originally in addiction treatment contexts where they appeared to reduce withdrawal symptoms. The application to longevity and performance is more recent.

What Human Research Shows

Human data on NAD+ administration is more substantial than for many other longevity compounds:

Metabolic Health

A randomised controlled trial published in Cell Metabolism (Yoshino et al., 2021) found that NMN supplementation improved muscle insulin sensitivity in postmenopausal women with prediabetes. This was accompanied by increased NAD+ levels in peripheral blood mononuclear cells — providing a mechanistic link.

Muscle Function and Exercise Capacity

A 2022 study examined NMN's effects on physical performance in middle-aged adults, finding improvements in walking speed and grip strength alongside increased NAD+ metabolite levels. The effect sizes were modest but statistically significant.

Cognitive Research

Preclinical models show NAD+ repletion protects against neurodegeneration, including models of Alzheimer's and Parkinson's pathology. Human cognitive trials are underway but results remain preliminary.

Safety Profile

NAD+ administration has a well-documented safety record from decades of clinical use. IV infusions can cause transient side effects — flushing, nausea, chest tightness — that are rate-dependent and typically resolve by slowing the infusion. No serious long-term adverse events have been established.

NAD+ and the Longevity Stack

NAD+ is frequently combined with other longevity-oriented compounds in functional medicine protocols. Common research pairings include:

• Epithalon: A tetrapeptide researched for telomere maintenance and pineal gland regulation. Both target cellular ageing from different angles.
• BPC-157: For mitochondrial resilience alongside tissue repair.
• Resveratrol and quercetin: Oral sirtuin activators often stacked with NAD+ precursors to amplify sirtuin pathway activity.

Finding Providers

NAD+ IV therapy and subcutaneous protocols are offered by a wide range of functional medicine clinics and longevity-focused telehealth platforms. Many providers offer NAD+ as a standalone infusion or as part of a broader optimisation panel.

Browse providers offering NAD+ on the NAD+ peptide page or search the provider directory filtered to your region.

Research Summary

Property	Detail
Classification	Dinucleotide coenzyme (not a traditional peptide)
Research category	Longevity / cellular energy
Primary studied effects	Mitochondrial function, DNA repair, sirtuin activation, metabolic health
Evidence base	Animal models (extensive) + growing human trial data
Administration	IV infusion, subcutaneous injection, oral precursors (NMN/NR)
Safety profile	Well-established; transient infusion side effects possible
Regulatory status	Not FDA-approved as a drug; available as supplement precursors; IV from licensed providers

The research case for NAD+ is stronger than for most longevity compounds — it has both mechanistic plausibility and a growing body of human trial data. Whether IV delivery offers meaningfully superior outcomes to high-quality oral precursors remains an active debate. A licensed provider can help assess which approach fits your specific health context.

---

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before considering any therapeutic protocol.